1. Scrip

Interview: Almirall CEO Guenter Plots 'Play To Win' Future

 
• By Eleanor Malone

Peter Guenter has steadied the ship at Almirall, and after seven months in the role he outlines his vision for the company in his first exclusive interview as CEO of Spain's largest pharma company.

Almirall headquarters
Guenter has high hopes for Almirall • Source: Almirall

Peter Guenter has just finalized his five-year plan for Almirall SA after taking time to understand the company in his first seven months as CEO. In his first exclusive interview since joining the company, he tells Scrip about his vision for the dermatology-focused, family-controlled Spanish company.

When Guenter's appointment was announced, Almirall was reeling from damaging developments in its US business which had dragged down its sales and earnings and forced it to lower its financial guidance for 2017

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

More from Scrip

‘Market Developments’ Persuade Galapagos To Rethink Spin-Off

 
• By Andrew McConaghie

CEO Paul Stoffels exits early to be succeeded by Henry Gosebruch, who will now consider ‘all options’ for the Belgian firm as it tries to claw back investor confidence.

Strong Showing For Bayer’s Pharma Business In Uncertain Times

 
• By Kevin Grogan

As CEO Anderson backs high prices for innovative drugs in Europe

Stock Watch: Stock Watch: Lilly And Novo Duke Out Q1

 
• By Andy Smith

Novo Nordisk enjoyed a surprise GLP-1 agonist contracting win in the first quarter of 2025. This provided a welcome boost to its stock after it had spent the previous quarter on the back foot against rival Lilly.